Clene Inc. (NASDAQ: CLNN) Unites Physics, Chemistry, Material Science, and Biology to Address Neurodegenerative Diseases With The Company’s Unique CNM-Au8(R) Pipeline
An innovative combination of insights from physics, chemistry, materials science, and biology positions the new nanomedicine CNM-Au8(R) to address neurodegenerative disease, such as ALS, from a new angle The FDA has offered guidance to Clene on CNM-Au8’s application, with discussions ongoing for the possibility of accelerated approval on the basis of improved survival, biomarker, and clinical efficacy data in people living with ALS With plans…